Adjuvant therapy of melanoma
โ
Sanjiv S. Agarwala; John M. Kirkwood
๐
Article
๐
1998
๐
John Wiley and Sons
๐
English
โ 59 KB
๐ 1 views
Patients with AJCC Stage IIB and III melanoma have a poor 5-year survival rate which has been the driving force behind attempts to find an effective adjuvant therapy for this stage of disease that would effectively reduce relapse and improve survival. Immunotherapy with bacillus Calmette-Guerin (BCG